Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Biological: peginterferon alfa-2b
Other: laboratory biomarker analysis
Drug: decitabine

First Posted Date: 2008-06-19

Last Posted Date: 2014-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00701298

Locations: 🇺🇸
Nevada Cancer Institute-Summerlin Campus, Las Vegas, Nevada, United States

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Recurrent Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7
Male Breast Carcinoma

Interventions: Biological: Cixutumumab
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Temsirolimus

First Posted Date: 2008-06-18

Last Posted Date: 2018-06-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00699491

Locations: 🇺🇸
Palo Alto Medical Foundation Health Care, Palo Alto, California, United States
🇺🇸
Valley Medical Oncology Consultants, Pleasanton, California, United States
🇺🇸
The Medical Center of Aurora, Aurora, Colorado, United States

and more 189 locations

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-Small Cell Lung Carcinoma
Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Pemetrexed Disodium
Drug: Sunitinib Malate

First Posted Date: 2008-06-17

Last Posted Date: 2022-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 130

Registration Number: NCT00698815

Locations: 🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States
🇺🇸
Arroyo Grande Community, Arroyo Grande, California, United States
🇺🇸
Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States

and more 126 locations

Screening for Barrett's Esophagus in Otolaryngology Patients

Not Applicable

Completed

Conditions: Cough
Throat Clearing
Extraesophageal Symptoms
Hoarseness
Difficulty Swallowing

Interventions: Diagnostic Test: Screening for Barrett's Esophagus

First Posted Date: 2008-06-11

Last Posted Date: 2018-03-06

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 295

Registration Number: NCT00695227

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2008-06-09

Last Posted Date: 2015-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00693433

Locations: 🇺🇸
Veteran's Administration Medical Center, Las Angeles, California, United States

Circuit Training and Motivational Interviewing to Reduce Type 2 Diabetes in Youth

Not Applicable

Completed

Conditions: Obesity and Type 2 Diabetes

Interventions: Behavioral: Circuit Training
Behavioral: Circuit training + motivational interviewing

First Posted Date: 2008-06-09

Last Posted Date: 2017-09-25

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 45

Registration Number: NCT00693511

Locations: 🇺🇸
Veronica Atkins Lifestyle Intervention Laboratory, Los Angeles, California, United States

Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Phase 3

Completed

Conditions: Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Other: Placebo
Other: Quality-of-Life Assessment
Drug: Sunitinib Malate

First Posted Date: 2008-06-09

Last Posted Date: 2019-06-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 210

Registration Number: NCT00693992

Locations: 🇺🇸
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
🇺🇸
Providence Hospital, Mobile, Alabama, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 477 locations

Predicting Weight Gain and Weight Loss Associated With Overeating or Fasting

Phase 2

Completed

Conditions: Weight Gain
Nutrition Therapy
Weight Loss
Obesity
Diet Therapy

Interventions: Behavioral: Overfeeding
Behavioral: Weight Loss
Behavioral: Overfeeding Low Pro

First Posted Date: 2008-05-30

Last Posted Date: 2025-06-26

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 83

Registration Number: NCT00687115

Locations: 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase 1

Terminated

Conditions: Recurrent Renal Cell Cancer
Renal Cell Carcinoma
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Biological: bevacizumab
Drug: etaracizumab

First Posted Date: 2008-05-28

Last Posted Date: 2014-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT00684996

Locations: 🇺🇸
Fremont - Rideout Cancer Center, Marysville, California, United States
🇺🇸
University of California at Davis Cancer Center, Sacramento, California, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

and more 2 locations

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Phase 2

Completed

Conditions: HER2 Positive Breast Carcinoma
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Drug: Capecitabine
Drug: Lapatinib Ditosylate
Biological: Cixutumumab
Other: Quality-of-Life Assessment

First Posted Date: 2008-05-28

Last Posted Date: 2020-03-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT00684983

Locations: 🇺🇸
Providence Hospital, Mobile, Alabama, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States

and more 385 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy